This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
PHILADELPHIA, Sept. 6, 2012 (GLOBE NEWSWIRE) --
Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company"), today announced that the Company will participate in the Rodman & Renshaw 14th Annual Healthcare Conference, to be held on September 9 - 11, 2012 at the Waldorf Astoria, New York, NY.
Hemispherx's presentation is scheduled for Tuesday, September 11, 2012 at 2:50 PM EDT in the Starlight North room.
The presentation will be webcast live. Listeners can access this broadcast through Hemispherx`s website at
http://www.hemispherx.net . The webcast will be available for 30 days following the presentation.
The Company will also be participating in one-on-one meetings with conference attendees and will discuss the Company's products and global investigational programs for the treatment and prevention of infectious diseases including Chronic Fatigue Syndrome, genital warts, influenza and cancer: Alferon N Injection
®, Alferon LDO
® and Ampligen
®. To schedule a one-one-one meeting with the Company at this event, please contact a Rodman & Renshaw representative directly or contact Dianne Will at (518) 398-6222.
For more information regarding this conference, please visit
About Hemispherx Biopharma
Hemispherx Biopharma, Inc. is an advanced specialty pharmaceutical company engaged in the manufacture and clinical development of new drug entities for treatment of seriously debilitating disorders. Hemispherx's flagship products include Alferon N Injection
® (FDA approved for a category of sexually transmitted diseases) and the experimental therapeutics Ampligen
® and Alferon
® LDO. Because both Ampligen
® and Alferon
® LDO are experimental in nature, they are not designated safe and effective by a regulatory authority for general use and are legally available only through clinical trials with the referenced disorders. Ampligen
® is an experimental RNA nucleic acid being developed for globally important debilitating diseases and disorders of the immune system including Chronic Fatigue Syndrome. Hemispherx's platform technology includes components for potential treatment of various severely debilitating and life threatening diseases. Hemispherx has patents comprising its core intellectual property estate and a fully commercialized product (Alferon N Injection
®). The Company wholly owns and exclusively operates a GMP certified manufacturing facility in the United States for commercial products. For more information please visit
To the extent that statements in this press release are not strictly historical, all such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Words such as "hopes," "believes," "plans," "anticipates," and similar expressions are intended to identify forward-looking statements. These statements are based on the company's current beliefs and expectations and represent the Company's judgment as of the date of this release. The inclusion of forward-looking statements should not be regarded as a representation by Hemispherx that any of its plans will be achieved. These forward-looking statements are neither promises nor guarantees of future performance, and are subject to a variety of risks and uncertainties, many of which are beyond Hemispherx's control, which could cause actual results to differ materially from those contemplated in these forward-looking statements. Examples of such risks and uncertainties include those set forth in the Disclosure Notice, above, as well as the risks described in Hemispherx's filings with the Securities and Exchange Commission, including the most recent reports on Forms 10-K, 10-Q and 8-K. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Hemispherx undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise revise or update this release to reflect events or circumstances after the date hereof.
CONTACT: Company/Investor Contact:
Hemispherx Biopharma, Inc.